Geron Soars After Study Shows Bone Marrow Drug’s Benefit
This article is for subscribers only.
Geron Corp. rose as much as 18 percent after a Mayo Clinic study found the biotechnology company’s experimental drug imetelstat helped patients with a bone marrow cancer.
Geron increased 4.4 percent to $6.13 at 10:09 a.m. New York time after reaching $6.92, the highest intraday price since Nov. 7. The Menlo Park, California-based company’s shares had climbed more than fourfold this year through yesterday.